GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cell MedX Corp (OTCPK:CMXC) » Definitions » Cash-to-Debt

Cell MedX (Cell MedX) Cash-to-Debt : 0.25 (As of Feb. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Cell MedX Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cell MedX's cash to debt ratio for the quarter that ended in Feb. 2024 was 0.25.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Cell MedX couldn't pay off its debt using the cash in hand for the quarter that ended in Feb. 2024.

The historical rank and industry rank for Cell MedX's Cash-to-Debt or its related term are showing as below:

CMXC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0   Med: 0.08   Max: No Debt
Current: 0.25

During the past 12 years, Cell MedX's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.08.

CMXC's Cash-to-Debt is ranked worse than
83.41% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs CMXC: 0.25

Cell MedX Cash-to-Debt Historical Data

The historical data trend for Cell MedX's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cell MedX Cash-to-Debt Chart

Cell MedX Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.09 0.07 0.04 0.10

Cell MedX Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.10 0.06 0.02 0.25

Competitive Comparison of Cell MedX's Cash-to-Debt

For the Medical Devices subindustry, Cell MedX's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cell MedX's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cell MedX's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cell MedX's Cash-to-Debt falls into.



Cell MedX Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cell MedX's Cash to Debt Ratio for the fiscal year that ended in May. 2023 is calculated as:

Cell MedX's Cash to Debt Ratio for the quarter that ended in Feb. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cell MedX  (OTCPK:CMXC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Cell MedX Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cell MedX's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Cell MedX (Cell MedX) Business Description

Traded in Other Exchanges
N/A
Address
123 W. Nye Lane, Suite 446, Carson City, NV, USA, 89706
Cell MedX Corp is an early stage development company focused on the discovery, development and, commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage the illness and related complications. The company's product portfolio consists of electromedical technologies, ebalance, and others.
Executives
Richard Jeffs 10 percent owner FLAT 7, 6 ENNISMORE GARDENS, LONDON X0 SW7 1NL
Dwayne Yaretz director, officer: Chief Executive Officer SUITE 1050 WEST PENDER STREET SUITE 2250, VANCOUVER A1 V6E 3S7
Bradley S Hargreaves 10 percent owner 904-1616 BAYSHORE DR, VANCOUVER A1 V6G3L1
Frank Mcenulty director, officer: CEO, CFO, Treas., Sec 4182 N. VIKING WAY, SUITE 216, LONG BEACH CA 90808-1475
Joao Dacosta director, officer: COO #810 - 789 WEST PENDER STREET, VANCOUVER A1 V6C 1H2
George Adams director 7535 CONSERVATION ROAD, GUELPH A6 N1H6J1
Terrance George Owen director, officer: CEO 635 FOURTH LINE (UNIT 1), OAKVILLE A6 L6L 5BO
John David Sanderson officer: Chief Medical Officer 9 ISLANDVIEW, IRVINE CA 92604
Yanika S Silina officer: CFO, Treasurer and Secretary 789 WEST PENDER STREET, UNIT 810, VANCOUVER A1 V6C 1H2
Jean M Arnett 10 percent owner 121 - 3989 HENNING DRIVE, BURNABY A1 V5C 6P8
Ean Kremer director, officer: Chief Technology Officer C/O PLANDEL RESOURCES, INC., 4575 DEAN MARTIN DRIVE, STE. 2206, LAS VEGAS NV 89103

Cell MedX (Cell MedX) Headlines

From GuruFocus

Cell MedX Insider Buys 22,500 Shares

By Kyle Ferguson Kyle Ferguson 11-11-2016